Savara (NASDAQ:SVRA) Stock Price Down 5.3% – Should You Sell?

Shares of Savara Inc (NASDAQ:SVRA) traded down 5.3% on Thursday . The stock traded as low as $2.90 and last traded at $2.93. 392,669 shares changed hands during mid-day trading, a decline of 58% from the average session volume of 929,169 shares. The stock had previously closed at $3.09.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the company. Wells Fargo & Company assumed coverage on Savara in a research report on Friday, December 20th. They issued an “overweight” rating and a $8.00 price objective for the company. JMP Securities reissued a “market outperform” rating and issued a $9.00 price objective on shares of Savara in a research report on Thursday, December 19th. HC Wainwright lowered their price objective on Savara from $10.00 to $6.00 and set a “buy” rating for the company in a research report on Wednesday, November 13th. Finally, Evercore ISI reissued an “in-line” rating and issued a $5.00 price objective (down from $7.00) on shares of Savara in a research report on Wednesday, November 13th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat.com, Savara currently has a consensus rating of “Moderate Buy” and an average price target of $9.86.

Savara Price Performance

The firm has a market capitalization of $502.85 million, a P/E ratio of -6.81 and a beta of 0.68. The business has a 50-day moving average of $3.23 and a 200 day moving average of $3.86. The company has a current ratio of 17.70, a quick ratio of 17.70 and a debt-to-equity ratio of 0.13.

Savara (NASDAQ:SVRA) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.11) EPS for the quarter, hitting analysts’ consensus estimates of ($0.11). On average, sell-side analysts predict that Savara Inc will post -0.45 earnings per share for the current fiscal year.

Insider Transactions at Savara

In other Savara news, Director Joseph S. Mccracken bought 20,000 shares of the business’s stock in a transaction dated Tuesday, November 19th. The shares were purchased at an average price of $2.95 per share, for a total transaction of $59,000.00. Following the purchase, the director now directly owns 210,837 shares of the company’s stock, valued at approximately $621,969.15. This represents a 10.48 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Matthew Pauls sold 54,702 shares of the business’s stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $3.31, for a total value of $181,063.62. Following the completion of the transaction, the chief executive officer now owns 1,536,379 shares in the company, valued at $5,085,414.49. The trade was a 3.44 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 5.13% of the company’s stock.

Hedge Funds Weigh In On Savara

Institutional investors have recently bought and sold shares of the company. Vestal Point Capital LP lifted its stake in Savara by 24.7% in the third quarter. Vestal Point Capital LP now owns 8,090,000 shares of the company’s stock valued at $34,302,000 after purchasing an additional 1,600,000 shares during the last quarter. Frazier Life Sciences Management L.P. lifted its stake in Savara by 103.9% in the second quarter. Frazier Life Sciences Management L.P. now owns 8,157,385 shares of the company’s stock valued at $32,874,000 after purchasing an additional 4,157,385 shares during the last quarter. Geode Capital Management LLC lifted its stake in Savara by 10.8% in the third quarter. Geode Capital Management LLC now owns 2,726,850 shares of the company’s stock valued at $11,564,000 after purchasing an additional 264,825 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in Savara by 238.4% in the third quarter. Charles Schwab Investment Management Inc. now owns 911,617 shares of the company’s stock valued at $3,865,000 after purchasing an additional 642,259 shares during the last quarter. Finally, Nantahala Capital Management LLC lifted its position in shares of Savara by 198.2% during the second quarter. Nantahala Capital Management LLC now owns 5,180,951 shares of the company’s stock worth $20,879,000 after acquiring an additional 3,443,541 shares in the last quarter. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.